|1.||Boulikas, Teni: 7 articles (09/2010 - 07/2004)|
|2.||Fortin, David: 3 articles (06/2015 - 04/2010)|
|3.||Paquette, Benoit: 3 articles (06/2015 - 04/2010)|
|4.||Sanche, Léon: 3 articles (06/2015 - 04/2010)|
|5.||Froudarakis, Marios E: 3 articles (04/2011 - 01/2007)|
|6.||Mongiat, Maurizio: 2 articles (11/2014 - 12/2013)|
|7.||Celegato, Marta: 2 articles (11/2014 - 12/2013)|
|8.||Borghese, Cinzia: 2 articles (11/2014 - 12/2013)|
|9.||Casagrande, Naike: 2 articles (11/2014 - 12/2013)|
|10.||Colombatti, Alfonso: 2 articles (11/2014 - 12/2013)|
07/01/2005 - "Systemic Lipoplatin infusion results in preferential tumor uptake in human studies."
12/01/2013 - "The ability of R-ME-180 cells to form spheroids in vitro and tumors in nude mice was also remarkably decreased by lipoplatin. "
08/01/2009 - "During clinical development, 10- to 200-fold higher accumulation of Lipoplatin in solid tumors compared to adjacent normal tissue was found in patients. "
11/01/2008 - "Activity of lipoplatin in tumor and in normal cells in vitro."
03/01/2006 - "MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2009 - "Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer."
05/01/2010 - "Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer."
11/01/2008 - "The aims of this preclinical study were to compare lipoplatin and cisplatin cytotoxicity in vitro in established cell lines derived from non-small cell lung cancer, renal cell carcinoma, and in normal hematopoietic cell precursors, and to identify biological markers associated with sensitivity and resistance. "
03/01/2006 - "Clonogenic data revealed a significant (P<0.05) 2-fold resistance to lipoplatin of HCT116 human colorectal adenocarcinoma cells lacking MLH1, one of five proteins crucial to MMR function, as compared to MLH1-expressing HCT116 cells. "
07/01/2005 - "We explored the hypothesis that intravenous infusion of Lipoplatin results in tumor targeting in four independent patient cases (one with hepatocellular adenocarcinoma, two with gastric cancer and one with colon cancer) who underwent Lipoplatin infusion followed by a prescheduled surgery approximately 20 h later. "
11/01/2006 - "Human colorectal adenocarcinoma sublines either deficient (HCT116+ch2) or proficient (HCT116+ch3) in the function of MLH1, one of five proteins crucial to DNA mismatch repair (MMR), were used to investigate whether the Akt-specific inhibitor LY294005 could not only increase the efficacy of platinum drugs in HCT116 cells in general but also increase the efficacy of the cisplatinum compounds Cisplatin and Lipoplatin specifically in MLH1-deficient, Cisplatin- and Lipoplatin-resistant HCT116 cells. "
06/01/2015 - "Convection-enhancement delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model."
04/01/2010 - "Lipoplatin(TM), and Lipoxal(TM), the liposomal formulations of cisplatin and oxaliplatin respectively, were tested on the F98 glioma cells for their ability to improve the cell uptake and increase the synergic effect when combined with ionizing radiation. "
09/01/2012 - "In this study, cisplatin, oxaliplatin, carboplatin, Lipoplatin (the liposomal formulation of cisplatin), and Lipoxal (the liposomal formulation of oxaliplatin) were tested on F98 glioma orthotopically implanted in Fischer rats. "
06/01/2015 - "In this study, we use convection-enhanced delivery (CED) to deliver the platinum-based drugs (cisplatin, carboplatin, and Lipoplatin(TM) - liposomal formulation of cisplatin) directly into the tumor of F98 glioma-bearing rats that were subsequently treated with γ radiation (15 Gy). "
02/01/2009 - "We observed G1-G2 toxicity during chemotherapy, mainly gastrointestinal with nausea and vomiting (4 patients), asthenia (3 patients), mucositis (2 patients) and anemia (4 patients).Our phase ii study does not support a more extensive use of lipoplatin in phase III studies. "
08/01/2009 - "Lipoplatin is a liposomal cisplatin encapsulated into liposome nanoparticles of an average diameter of 110 nm. Lipoplatin has substantially reduced the renal toxicity, peripheral neuropathy, ototoxicity, myelotoxicity as well as nausea/vomiting and asthenia of cisplatin in Phase I, II and III clinical studies with enhanced or similar efficacy to cisplatin. "
|4.||Proteins (Proteins, Gene)
|9.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)